[Arsenic trioxide treatment in a patient with recurrent acute promyelocytic leukemia (APL)]

M L Moreno Tejero; A Lassaletta Atienza; A García Salido; J Sevilla Navarro; L Madero López

doi:10.1016/j.anpedi.2010.04.010

[Arsenic trioxide treatment in a patient with recurrent acute promyelocytic leukemia (APL)]

An Pediatr (Barc). 2010 Jul;73(1):39-41. doi: 10.1016/j.anpedi.2010.04.010. Epub 2010 Jun 4.

[Article in Spanish]

Authors

M L Moreno Tejero¹, A Lassaletta Atienza, A García Salido, J Sevilla Navarro, L Madero López

Affiliation

¹ Hospital Universitario del Niño Jesús, Madrid, España. [email protected]

PMID: 20605542
DOI: 10.1016/j.anpedi.2010.04.010

Abstract

Acute promyelocytic leukemia (APL) is a special subtype of acute myeloid leukemia (AML) with M3 morphology and specific chromosomal translocation t(15;17) with resultant leukemogenic PML-RARalpha fusion gene. Its main characteristics are therapy response using all-trans-retinoic acid (ATRA) and its high rate of recovery; higher than other subtypes of acute myeloid leukemia. Arsenic trioxide induces a high complete remission rate in patients having an APL relapse. Experience in the use of this drug is still limited in the field of Paediatrics.

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / therapeutic use*
Arsenic Trioxide
Arsenicals / therapeutic use*
Child
Humans
Leukemia, Promyelocytic, Acute / drug therapy*
Male
Oxides / therapeutic use*
Recurrence

Substances

Antineoplastic Agents
Arsenicals
Oxides
Arsenic Trioxide